Whitelab Genomics, a Paris, France- and Cambridge (MA)-based developer of genomics medicines via technology powered by artificial intelligence (AI), raised 10m in Series A funding.
Backers included Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and Omnes Capital.
The company intends to usr the funds for growth of R&D team and US operations.
Founded in 2019 by David Del Bourgo, MBA, and Julien Cottineau, Ph.D., alongside a team of world-class data scientists specialized in AI, computational biologists, Whitelab Genomics offers in-silico simulations customized for target discovery, vector, and payload design, genotoxicity assessment and identification of experimental protocols of in vitro and in vivo strategies.
The company supports its clients through the in-silico development phases enabling them to quickly develop target vectors and payloads and save time needed to give patients access to new genomic therapies.